Datasea Intelligent Technology Ltd (DTSS) News & EventsDTSSDatasea Intelligent Technology Ltd

Datasea Expands Strategic Cooperation with Nanjing Linghang to Develop AI Elderly Care Robots

Datasea Intelligent Technology announced that the Company's related Chinese operating entity plans to further expand its strategic cooperation with Nanjing Linghang Intelligent Aviation Technology to jointly develop AI-powered elderly care robot solutions and related digital service platforms. The expanded cooperation marks Datasea's entry into the rapidly growing AI elderly care robotics sector and represents an important step in the Company's strategy to participate in China's trillion-RMB silver economy. Under the proposed cooperation, Datasea plans to contribute its AI agent, multimodal data processing, digital platform, software development and data analytics capabilities, effectively providing the intelligent "brain" and digital service layer for elderly care robots. Linghang Intelligent is expected to contribute robot hardware, mechanical systems, motion control, sensor integration, manufacturing, system integration and scenario-based deployment capabilities. By combining these complementary capabilities, the parties intend to jointly develop AI elderly care robot solutions for a broad range of applications, including home-based elderly care, community elderly care, nursing homes, rehabilitation centers, healthcare institutions and other senior care environments. China's rapidly aging population is creating significant demand for more efficient, intelligent and scalable elderly care services. The proposed cooperation is designed around a complementary model in which Datasea provides the AI and digital intelligence layer while Linghang Intelligent provides the physical robotics platform and deployment capabilities.

Datasea's NeuroVibe Biofeedback System Completes FDA Registration

Datasea's variable interest entity in China, Shuhai Jingwei, has completed establishment registration and device listing with the FDA for its NeuroVibe Biofeedback System, including products NV-02 and NV-03. The products are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the Neurology regulatory area. FDA establishment registration and device listing do not constitute FDA approval, clearance or authorization of the establishment or the listed devices. The company believes that initiation of FDA establishment registration and device listing for NeuroVibe and their listing is a step forward from the R&D stage to a more clearly defined, regulated product platform with a potential for commercial deployment. NeuroVibe is able to collect and analyze human physiological signals and provide real-time biofeedback to support neurological function assessment and training, brain health management and related wellness-oriented applications.

Datasea Advances FDA Registration Procedures

Datasea Intelligent Technology announced that the company is advancing compliance work and related procedures required for U.S. Food and Drug Administration establishment registration and device listing for one of its acoustic brain-computer interface products. The Company has submitted its Dun & Bradstreet Data Universal Numbering System application, which is one of the administrative steps that support future FDA-related registration activities. The Company expects to continue evaluating and preparing for potential establishment registration, device listing and related regulatory procedures in accordance with applicable FDA requirements. These efforts represent an important preliminary step in the Company's international strategy for its acoustic medical and BCI-related product portfolio. The product is based on the Company's acoustic medical and BCI technology roadmap and integrates four core capabilities: acoustic stimulation, bone-conduction neuromodulation, EEG signal acquisition and AI-assisted health management. It is designed to focus on non-invasive acoustic neuromodulation-related application scenarios, with potential applications across neurological health fields, including brain health management, rehabilitation support, cognitive function monitoring, sleep quality optimization and emotional regulation. The Company believes that the integration of acoustic intervention, physiological signal monitoring and AI-based analysis provides a differentiated technical pathway compared with traditional invasive BCI approaches, and may offer potential advantages in safety profile, product accessibility, user compliance and future commercialization scalability.